Charcot-Marie-Tooth disease
MONDO:0015626An inherited degenerative disorder involving the peripheral nerves. It is caused by mutations in the genes that are responsible for the production of proteins necessary for the function and structure of the peripheral nerves. It is characterized by muscle atrophy and weakness in the feet, legs, hands, and arms and loss of sensation in the limbs.
Also known as: hereditary motor and sensory neuropathy, hereditary sensorimotor neuropathy, CMT, CMT/HMSN, Charcot Marie Tooth muscular atrophy, Charcot-Marie-Tooth disease, Charcot-Marie-Tooth hereditary neuropathy, peroneal muscular atrophy
83 clinical trials for this condition and its sub-types, 52 tagged with Charcot-Marie-Tooth disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Charcot-Marie-Tooth disease
-
Charcot-Marie-Tooth disease type 1 4 trials · 40 incl. sub-types
6 sub-types
- Charcot-Marie-Tooth disease type 1F 21 trials
- Charcot-Marie-Tooth disease type 1A 16 trials
- Charcot-Marie-Tooth disease type 1B 3 trials
- Charcot-Marie-Tooth disease type 1C 1 trial
- Charcot-Marie-Tooth disease type 1D 1 trial
- Charcot-Marie-Tooth disease type 1E 1 trial
-
Charcot-Marie-Tooth disease type 2 3 trials · 9 incl. sub-types
39 sub-types
- Charcot-Marie-Tooth disease axonal type 2S 3 trials
- Charcot-Marie-Tooth disease type 2A1 2 trials
- Charcot-Marie-Tooth disease type 2A2 2 trials
- Charcot-Marie-Tooth disease type 2D 2 trials
- Charcot-Marie-Tooth disease type 2J 2 trials
- Charcot-Marie-Tooth disease axonal type 2C 1 trial
- Charcot-Marie-Tooth disease axonal type 2H 1 trial
- Charcot-Marie-Tooth disease axonal type 2L 1 trial
- Charcot-Marie-Tooth disease axonal type 2N 1 trial
- Charcot-Marie-Tooth disease axonal type 2O 1 trial
- Charcot-Marie-Tooth disease axonal type 2P 1 trial
- Charcot-Marie-Tooth disease axonal type 2Q 1 trial
- Charcot-Marie-Tooth disease axonal type 2U 1 trial
- Charcot-Marie-Tooth disease type 2B1 1 trial
- Charcot-Marie-Tooth disease type 2B2 1 trial
- Charcot-Marie-Tooth disease type 2B5 1 trial
- Charcot-Marie-Tooth disease type 2E 1 trial
- Charcot-Marie-Tooth disease type 2I 1 trial
- Charcot-Marie-Tooth disease type 2R 1 trial
- Charcot-Marie-Tooth disease type 2T 1 trial
- Charcot-Marie-Tooth disease type 2Y 1 trial
- Autosomal dominant Charcot-Marie-Tooth disease type 2K 1 trial
- Autosomal dominant Charcot-Marie-Tooth disease type 2M 1 trial
- Charcot-Marie-Tooth disease axonal type 2CC 0 trials
- Charcot-Marie-Tooth disease axonal type 2F 0 trials
- Charcot-Marie-Tooth disease axonal type 2K 0 trials
- Charcot-Marie-Tooth disease axonal type 2T 0 trials
- Charcot-Marie-Tooth disease axonal type 2V 0 trials
- Charcot-Marie-Tooth disease axonal type 2X 0 trials
- Charcot-Marie-Tooth disease axonal type 2Z 0 trials
- Charcot-Marie-Tooth disease type 2B 0 trials
- Charcot-Marie-Tooth disease, axonal, type 2EE 0 trials
- Charcot-Marie-tooth disease, axonal, type 2DD 0 trials
- MME-related autosomal dominant Charcot Marie Tooth disease type 2 0 trials
- Autosomal dominant Charcot-Marie-Tooth disease type 2 due to KIF5A mutation 0 trials
- Autosomal dominant Charcot-Marie-Tooth disease type 2 due to TFG mutation 0 trials
- Autosomal dominant Charcot-Marie-Tooth disease type 2W 0 trials
- Autosomal dominant charcot-marie-tooth disease type 2 due to DGAT2 mutation 0 trials
- Giant axonal neuropathy 2 0 trials
-
Charcot-Marie-Tooth disease type 4 0 trials · 5 incl. sub-types
12 sub-types
- Charcot-Marie-Tooth disease type 4J 3 trials
- Charcot-Marie-Tooth disease type 4A 2 trials
- Charcot-Marie-Tooth disease type 4B1 2 trials
- Charcot-Marie-Tooth disease type 4B2 2 trials
- Charcot-Marie-Tooth disease type 4C 2 trials
- Charcot-Marie-Tooth disease type 4D 2 trials
- Charcot-Marie-Tooth disease type 4B3 1 trial
- Charcot-Marie-Tooth disease type 4E 1 trial
- Charcot-Marie-Tooth disease type 4F 1 trial
- Charcot-Marie-Tooth disease type 4H 1 trial
- Charcot-Marie-Tooth disease type 4G 0 trials
- Charcot-Marie-Tooth disease type 4K 0 trials
-
Intermediate Charcot-Marie-Tooth disease 0 trials · 3 incl. sub-types
3 sub-types
- Autosomal dominant intermediate Charcot-Marie-Tooth disease 0 trials · 3 incl. sub-types Sub-types →
- Autosomal recessive intermediate Charcot-Marie-Tooth disease 0 trials · 2 incl. sub-types Sub-types →
- Charcot-Marie-Tooth disease, dominant intermediate G 0 trials
-
Charcot-Marie-Tooth disease type X 1 trial · 2 incl. sub-types
6 sub-types
- Charcot-Marie-Tooth disease X-linked dominant 1 1 trial
- Charcot-Marie-Tooth disease X-linked dominant 6 0 trials
- Charcot-Marie-Tooth disease X-linked recessive 2 0 trials
- Charcot-Marie-Tooth disease X-linked recessive 3 0 trials
- Charcot-Marie-Tooth disease X-linked recessive 4 0 trials
- Charcot-Marie-Tooth disease X-linked recessive 5 0 trials
-
Charcot-Marie-Tooth disease type 3 0 trials
Most studied deeper sub-types
-
One-Patient trial hopes to fix rare nerve disease at its genetic root
Disease control OngoingThis study tests a custom-made drug (VCA-894A) in a single person with a rare genetic nerve disease called CMT2S. The drug is designed to correct a specific genetic error and restore a missing protein. The main goals are to check if the treatment is safe and if it can improve mus…
Phase 1/2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a One-Time gene injection halt nerve damage in CMT1A?
Disease control CancelledThis trial tests a one-time gene therapy injection for people with Charcot-Marie-Tooth disease type 1A (CMT1A), a genetic nerve disorder that causes progressive muscle weakness. The therapy delivers a gene that produces a protein to support nerve health. Three adults aged 18 to 3…
Phase 1/2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can wearable sensors and walking tests reliably track nerve damage?
Knowledge-focused OngoingResearchers are checking whether tests of muscle strength, walking, balance, and fine motor skills give consistent results in people with polyneuropathy. About 520 adults with various forms of nerve damage, plus healthy volunteers, take part. Participants complete physical tests,…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC